Twist Bioscience Q3 Sales Jump 60%, Raises FY22 Revenue Outlook Surpassing Consensus

Twist Bioscience Corporation TWST has reported a 60% Y/Y increase in its Q3 FY22 revenues to $56.1 million, beating the Wall Street estimate of $51.45.
The company shipped products to approximately 1,900 customers versus about 1,800 a year ago.
Twist Bioscience shipped approximately 163,000 genes during the quarter, compared with about 107,000 in Q3 FY21.
The company received total orders of $59.7 million compared to $39.1 million a year ago.
The company posted an EPS loss of $(1.08) per share, beating the consensus of $(1.31) and wider than a loss of $(0.82) posted a year ago.
Twist held $527.6 million in cash and equivalents at the end of the quarter.
FY22 Guidance: Twist Bioscience expects FY22 sales of $203 million, an increase from previous guidance of $191- $199 million, beating the analyst estimate of $196.91 million.
The guidance includes SynBio revenue of $80 million, up from $71-$73 million expected earlier.
NGS revenue is estimated to be approximately $97 million, an increase from previous guidance of $94 million to $96 million
Biopharma revenue is estimated to be approximately $26 million, at the low end of the previous guidance range of $26 - $30 million.
Price Action: TWST shares are up 2.18% at $47.85 on the last check Friday.